MedTrace Logo

Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients

NCT01149382 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2012-08-21

No results posted yet for this study

Summary

Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown that the standard inactivated influenza vaccine has poor immunogenicity in this population. The investigators plan to test the humoral response to vaccination and look at HLA upregulation

Conditions

  • Transplant

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Deepali Kumar, MD · University of Alberta

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-08-31
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01149382 on ClinicalTrials.gov